(Reuters) - NEW YORK, July 31 - Cephalon Inc. reported a second-quarter loss on Tuesday as the biotechnology company was hit by legal costs and plunging sales of its cancer pain drug, Actiq, due to generic competition.
The Frazer, Pennsylvania-based company posted a net loss of $4.3 million, or 6 cents per share, compared with a net profit of $50.4 million, or 76 cents per share, a year ago.
Read more at Reuters.com Market News
The Frazer, Pennsylvania-based company posted a net loss of $4.3 million, or 6 cents per share, compared with a net profit of $50.4 million, or 76 cents per share, a year ago.
Read more at Reuters.com Market News
No comments:
Post a Comment